ClinicalTrials.gg
CompletedNCT04692623CTUpdated Apr 12, 2023

EFFECTS OF MOXIFLOXACIN AND GEMIFLOXACIN ON BLOOD GLUCOSE AND ECG MORPHOLOGY OF EUGLYCEMICS:A CLINICAL STUDY

A Phase 1 interventional study of Moxifloxacin 400mg and Gemifloxacin 320 MG in Blood Glucose, Low and Hypoglycemia, sponsored by Shaheed Benazir Bhutto University Sheringal Dir Upper. Completed at 1 site in Pakistan. Open to male participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-12.

Sponsored by Shaheed Benazir Bhutto University Sheringal Dir Upper · Phase 1, Interventional, and Screening

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Male
01

Study summary

EFFECTS OF MOXIFLOXACIN AND GEMIFLOXACIN ON BLOOD GLUCOSE LEVEL OF EUGLYCEMICS:A PRE-CLINICAL AND CLINICAL STUDY.

Our aim and objectives are to:

  1. To check the possible effects of Moxifloxacin and Gemifloxacin in healthy volunteers for possible effects on blood glucose levels with a subsequent shift in serum insulin level of healthy volunteer (target population).
  2. ECG morphology effect. In the above entitled studies we are going to determine the effects of the above two 4th generation fluoroquinolones drugs on the blood glucose levels and ECG morphology effect.of euglycemics healthy volunteers.The drug will be gave as per approved standard adult dose.The drug is FDA approved and marketed drug.No risk is to the patient only 3-5 ml of the blood will be taken at baseline and after the drug completion at steady state concentration.
Read the detailed description

The study will be conducted under good clinical practice guidelines and a consent form will be signed from the healthy volunteers as per design of World health organization.The study has no harmful effects on the heaths of the volunteers as we are conducting the study for five dose/one pack drug will be gaven. The volunteers will be sampled randomly and the effect of the said drugs will be determined on blood glucose and insulin level.

Diabetes mellitus (DM), a non-communicable disease, which is considered now-a-days a life threatening disease to the human health (1,2).According to the report of International Diabetes Federation (IFD) and World Health Organization (WHO), diabetes mellitus is one of the World's fifth leading cause of mortality and about 415 million people of the world's population have diabetes mellitus in 2018 (3). After every 6 seconds, a person dies from diabetes mellitus (4, 5). Pakistan is a country with 7th highest diabetic population in the world and it is assumed to rise to 4th highest place by 2030 (6). Due to sedentary life style of People, there is a maximum increase of DM in the last decade (7). DM is classified into two classes i.e. Type I and Type II (8). The Type I diabetes is much more common. It is due to defective insulin secretion or insulin action or both (9). The Type II diabetes is now-a-days attributed to genetic disorders affecting the beta cells of the pancreas (10), or the ability of body cells to respond to insulin action leading to insulin resistance DM (11, 12).

Fluoroquinolones (FQs) are a group of antibacterial antibiotics. Newer fluoroquinolones has expanded its traditional coverage from Gram-negative coverage to Gram-positive as well as to anaerobic organisms (14-16). It has been used since 2-3 decades and has been observed to have excellent anti-microbial coverage, but unfortunately the FQs are associated with adverse drug events including strong dysglycemic effects which has also led to irreversible brain damage and even death (17). Till date, six different types of adverse drug reactions have been reported with Fluoroquinolones. These include prolongation of QT interval, Photo toxicity, hepatotoxicity and alteration in the blood glucose hemostasis (hyperglycemia or sometimes hypoglycemia), damage to the tendons leading to tendinitis (18). Canadian Adverse Drug Reaction Monitoring Program (CADRMP) reported that three marketed fluoroquinolones namely gatifloxacin, levofloxacin and moxifloxacilin are under Metabolic and Nutritional Disorders category. Among them Temafloxacin, levofloxacin and gatifloxacin have been reported to be associated with hemolysis (19).

It has been assumed that the dysglycemic effects of FQs mainly occur through their action on the ATP- sensitive K + channels. According to definition, an agent that causes the selective relaxation of an induced contractility due to low K+ (20-25 mM) is grouped as K+ channel opener. From the studies it can be assumed that fluoroquinolones may block the ATP-sensitive K+ channels as well as the opening of as Calcium channels that are voltage dependent (22). These opened Calcium channels further depolarize the membrane potential ultimately releasing insulin. These Studies reveals that fluoroquinolones have pancreatic beta cell cytotropic activity, however the dysglycemic effects of Moxifloxacin and Gemifloxacin have not been proven but very strong associations have been demonstrated via some case report studies (21).

Keeping in view all these studies and developments regarding the adverse effects associated with fluoroquinolones specially the dysglycemic effects due to cytotropic influence on the beta cells of the pancreas it is now very much needed to actually correlate these effects seen in the beta cells of the pancreas with the pancreatic tissue histopathological changes. Since, Moxifloxacin and Gemifloxacin are a new generation quinolones, thus our study focuses on them to get a clear picture of its possible shift of blood glucose and insulin in our society. Thus the hallmark of our study is to focus on dysglycemic effects (either hyperglycemic or hypoglycemic effects) associated with quinolones, it is not clear to get a clear picture on blood glucose level until it is tested in control environment of a preclinical study, and to translate the possible effects of the preclinical study in a controlled clinical trial of healthy volunteers who are euglycemics as well.

02

Conditions studied

  • Blood Glucose, Low
  • Hypoglycemia

Browse trials for

Keywords

  • ,Blood glucose,Serum insulin
03

In context

Hypoglycemia

706 studies on the registry are indexed under Hypoglycemia; 94 are open to participants now.

This study's enrollment of 25 is below the median of 28 across 534 interventional studies indexed under Hypoglycemia.

Browse Hypoglycemia studies →

Lead sponsor

Shaheed Benazir Bhutto University Sheringal Dir Upper is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteers having age from 20- 40 years
  • Non-Diabetic
  • Non-Alcoholics
  • Non-Smokers
  • Non-Hypertensive

Exclusion criteria

Exclusion Criteria:

  • Patients with prolongation in
  • Patients unwilling to give consent
  • Patients already on antibiotic therapy for a period one to two week or above.
  • Patients who are on other drugs that induces or decreases drug metabolism of quinolones.
  • Pregnant female patients.
  • Abuse of alcoholic beverages
  • Participants who are Allergic or to the said drug
  • Participants who have participated in a clinical trial within 3 months before the study period.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Screening
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Moxfloxacin Group

    In this arm 30 healthy volunteers were selected and they were given Moxifloxacin drug.

    Drug: Moxifloxacin 400mg

  • Experimental
    Gemifloxacin Group

    In this arm 30 healthy volunteers were selected and they were given Gemifloxacin

    Drug: Gemifloxacin 320 MG

Interventions

  • DrugMoxifloxacinStudies of MoxifloxacinMoxifloxacin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Blood will be checked for glucose levels and ECG at Baseline(Day Ist) and at Steady state Steady state(Tmax) via Glucometer and ECG machine will be used for determination of serum insulin levels.

    Also known as: Blood glucose and serum insulin

  • DrugGemifloxacin 320 MG

    Blood will be checked for glucose levels and ECG at Baseline(Day Ist) and at Steady state(Tmax) via Glucometer and ECG machine will be used for determination of serum insulin levels.

    Also known as: Blood glucose and serum insulin

06

What researchers measure

Primary outcomes

  1. Hypoglycemia expected as per case reports and studies

    Blood glucose level monitoring

    Time frame: 4 weeks

07

Study locations

1 site
  • Khyber Medical University,Peshawar
    Peshawar, Khyber Pukhtan Khawa 091, Pakistan
08

References and documents

Publications

  • Zimmet P. Globalization, coca-colonization and the chronic disease epidemic: can the Doomsday scenario be averted? J Intern Med. 2000 Mar;247(3):301-10. doi: 10.1046/j.1365-2796.2000.00625.x. PubMed 10762445 ↗
  • Ullah A, Ahmad S, Ali N, Rahman SU, Hussain H, Alghamdi S, Almehmadi M, Dablool AS, Bannunah AM, Bukhari SH, Almarshad F. Insulinotropic Potential of Moxifloxacin and Gemifloxacin: An In Vivo Rabbits Model Study Followed by Randomized Phase I Clinical Trial. Antibiotics (Basel). 2022 Jan 24;11(2):148. doi: 10.3390/antibiotics11020148. PubMed 35203750 ↗

Individual participant data

Plan to share: Yes — The data once obtained will be published in reputed journal

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: one month for complete data cllection and compilation

Access criteria: At the official website of Shaheed Benazir Bhutto University sheringal Dir upper

Data sharing details ↗ · www.sbbu.edu.pk

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Mar 2021, 0 months.

Of 21 phase 1 interventional studies under Hypoglycemia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 105. This study's 0 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2020
First posted
Jan 5, 2021
StartActual
Mar 1, 2021
Primary completionActual
Mar 15, 2021
CompletionActual
Apr 1, 2021
Last update
Apr 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04692623
Lead sponsor
Shaheed Benazir Bhutto University Sheringal Dir Upper
Collaborators
Khyber Medical University Peshawar
Responsible party
Dr Shujaat Ahmad (Associate Professor in Pharmacy,SBBU,Sheringal Dir Upper, Shaheed Benazir Bhutto University Sheringal Dir Upper) — Principal investigator
First posted
Jan 5, 2021
Start date
Mar 1, 2021
Primary completion
Mar 15, 2021
Completion
Apr 1, 2021
Last update
Apr 12, 2023

Study contacts

Abid Ullah, Ph.D Scholar
study chair · Departemt of Pharmacy,Shaheed Benazir Bhutto University,Sheringal Dir Upper,KP,Pakistan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Moxifloxacin

Start the discussion